VERA
Vera Therapeutics, Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.+108.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VERA vs CLDX
Revenue, margins, valuation, and 5-year total return — side by side.
CLDX
Celldex Therapeutics, Inc.
Biotechnology
Market Cap$2.22B
5Y Perf.+19.2%
VERA vs CLDX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VERA | CLDX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2.57B | $2.22B |
| Revenue (TTM) | $0.00 | $2M |
| Net Income (TTM) | $-369M | $-259M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -191.6% |
| Total Debt | $77M | $2M |
| Cash & Equiv. | $355M | $29M |
VERA vs CLDX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VERA
CLDX
| Stock | May 21 | May 26 | Return |
|---|---|---|---|
| Vera Therapeutics, … (VERA) | 100 | 208.0 | +108.0% |
| Celldex Therapeutic… (CLDX) | 100 | 119.2 | +19.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VERA vs CLDX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CLDX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Vera Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
VERA
Vera Therapeutics, Inc.
The Income Pick
VERA is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.35
- 212.0% 10Y total return vs CLDX's -43.3%
- Lower volatility, beta 1.35, Low D/E 12.8%, current ratio 13.64x
Best for: income & stability and long-term compounding
CLDX
Celldex Therapeutics, Inc.
The Growth Play
CLDX carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth -78.6%, EPS growth -59.2%, 3Y rev CAGR -14.0%
- -78.6% revenue growth vs VERA's -111.5%
- +76.2% vs VERA's +58.6%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CLDX | -78.6% revenue growth vs VERA's -111.5% |
| Quality / Margins | VERA | 2.3% margin vs CLDX's -172.5% |
| Stability / Safety | VERA | Beta 1.35 vs CLDX's 1.73 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CLDX | +76.2% vs VERA's +58.6% |
| Efficiency (ROA) | CLDX | -38.9% ROA vs VERA's -60.2%, ROIC -35.2% vs -54.6% |
VERA vs CLDX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
VERA vs CLDX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCLDXLAGGINGVERA
VERAVera Therapeutics, In…
1leads
CLDXCelldex Therapeutics,…
2leads
6 Total Categories
CATEGORYLEADERvs VERAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CLDX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CLDX7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
VERA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CLDX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CLDX and VERA operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | VERAVera Therapeutics… | CLDXCelldex Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $2M |
| EBITDAEarnings before interest/tax | -$382M | -$284M |
| Net IncomeAfter-tax profit | -$369M | -$259M |
| Free Cash FlowCash after capex | -$294M | -$213M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -191.6% |
| Net MarginNet income ÷ Revenue | — | -172.5% |
| FCF MarginFCF ÷ Revenue | — | -142.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -93.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -108.6% | -73.2% |
CLDX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — VERA and CLDX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | VERAVera Therapeutics… | CLDXCelldex Therapeut… |
|---|---|---|
| Market CapShares × price | $2.6B | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $2.2B |
| Trailing P/EPrice ÷ TTM EPS | -7.70x | -8.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1477.19x |
| Price / BookPrice ÷ Book value/share | 3.81x | 4.20x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — VERA and CLDX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CLDX leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
CLDX delivers a -41.7% return on equity — every $100 of shareholder capital generates $-42 in annual profit, vs $-75 for VERA. CLDX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to VERA's 0.13x. On the Piotroski fundamental quality scale (0–9), CLDX scores 3/9 vs VERA's 1/9, reflecting mixed financial health.
| Metric | VERAVera Therapeutics… | CLDXCelldex Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | -74.9% | -41.7% |
| ROA (TTM)Return on assets | -60.2% | -38.9% |
| ROICReturn on invested capital | -54.6% | -35.2% |
| ROCEReturn on capital employed | -48.1% | -44.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.13x | 0.00x |
| Net DebtTotal debt minus cash | -$277M | -$27M |
| Cash & Equiv.Liquid assets | $355M | $29M |
| Total DebtShort + long-term debt | $77M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -31.22x | — |
CLDX leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
VERA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VERA five years ago would be worth $31,200 today (with dividends reinvested), compared to $12,201 for CLDX. Over the past 12 months, CLDX leads with a +76.2% total return vs VERA's +58.6%. The 3-year compound annual growth rate (CAGR) favors VERA at 68.1% vs CLDX's -0.0% — a key indicator of consistent wealth creation.
| Metric | VERAVera Therapeutics… | CLDXCelldex Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | -26.2% | +23.4% |
| 1-Year ReturnPast 12 months | +58.6% | +76.2% |
| 3-Year ReturnCumulative with dividends | +374.6% | -0.1% |
| 5-Year ReturnCumulative with dividends | +212.0% | +22.0% |
| 10-Year ReturnCumulative with dividends | +212.0% | -43.3% |
| CAGR (3Y)Annualised 3-year return | +68.1% | -0.0% |
VERA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VERA and CLDX each lead in 1 of 2 comparable metrics.
Risk & Volatility
VERA is the less volatile stock with a 1.35 beta — it tends to amplify market swings less than CLDX's 1.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLDX currently trades 93.1% from its 52-week high vs VERA's 64.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VERAVera Therapeutics… | CLDXCelldex Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.35x | 1.73x |
| 52-Week HighHighest price in past year | $56.05 | $35.79 |
| 52-Week LowLowest price in past year | $18.76 | $17.85 |
| % of 52W HighCurrent price vs 52-week peak | +64.0% | +93.1% |
| RSI (14)Momentum oscillator 0–100 | 41.1 | 60.7 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 985K |
Evenly matched — VERA and CLDX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates VERA as "Buy" and CLDX as "Buy". Consensus price targets imply 116.3% upside for VERA (target: $78) vs 35.1% for CLDX (target: $45).
| Metric | VERAVera Therapeutics… | CLDXCelldex Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $77.60 | $45.00 |
| # AnalystsCovering analysts | 14 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CLDX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VERA leads in 1 (Total Returns). 2 tied.
Best OverallCelldex Therapeutics, Inc. (CLDX)Leads 2 of 6 categories
Loading custom metrics...
VERA vs CLDX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VERA or CLDX a better buy right now?
Analysts rate Vera Therapeutics, Inc.
(VERA) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VERA or CLDX?
Over the past 5 years, Vera Therapeutics, Inc.
(VERA) delivered a total return of +212. 0%, compared to +22. 0% for Celldex Therapeutics, Inc. (CLDX). Over 10 years, the gap is even starker: VERA returned +212. 0% versus CLDX's -43. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VERA or CLDX?
By beta (market sensitivity over 5 years), Vera Therapeutics, Inc.
(VERA) is the lower-risk stock at 1. 35β versus Celldex Therapeutics, Inc. 's 1. 73β — meaning CLDX is approximately 28% more volatile than VERA relative to the S&P 500. On balance sheet safety, Celldex Therapeutics, Inc. (CLDX) carries a lower debt/equity ratio of 0% versus 13% for Vera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — VERA or CLDX?
On earnings-per-share growth, the picture is similar: Celldex Therapeutics, Inc.
grew EPS -59. 2% year-over-year, compared to -69. 5% for Vera Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VERA or CLDX?
Vera Therapeutics, Inc.
(VERA) is the more profitable company, earning 0. 0% net margin versus -172. 5% for Celldex Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VERA leads at 0. 0% versus -191. 6% for CLDX. At the gross margin level — before operating expenses — CLDX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VERA or CLDX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VERA or CLDX better for a retirement portfolio?
For long-horizon retirement investors, Vera Therapeutics, Inc.
(VERA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+212. 0% 10Y return). Celldex Therapeutics, Inc. (CLDX) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VERA: +212. 0%, CLDX: -43. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VERA and CLDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.